Skip to content

Invest in the future of critical care

PiMed connected critical-care platform illustration

PlasmIT is building PiMed for hospitals across India's diverse care settings, bringing intelligent, integrated and immersive digital care into one platform. With a US$6B+ target market, validated hospital partnerships and commercial pilots ahead, PiMed is designed to help care teams access relevant information and support timely clinical intervention at scale.

The Opportunity

Critical-care teams still work across fragmented device information, making connected visibility harder to achieve. PiMed is designed to address that problem within a global intelligent ICU-care market.

  1. Fragmented device data

    Critical-care information is generated across many bedside devices and often remains separated across systems.

  2. Delayed clinical visibility

    Fragmented information makes it harder for care teams to see the whole patient picture when a timely decision is needed.

  3. US$6B+ target market

    An estimated target market of more than US$6 billion for intelligent ICU care.

  4. $200M+ India potential

    Potential revenue of more than $200 million in India by year five, subject to progressive hospital onboarding.

What investment can enable

Invest in the future of critical care

Conceptual connected-care network across an outline map of India

PlasmIT is building PiMed to serve an estimated US$6 billion market spanning approximately 9,000 hospitals, 110,000 ICU beds and 2.5 million general beds.

At scale, this represents the potential to support care delivery for approximately 6 million ICU patients and 400 million general-bed patients.

PiMed has reached MVP stage and is being prepared for commercial pilots. Leading hospitals in India have reviewed the solution, and PlasmIT has signed memoranda of understanding with hospital partners in India while building relationships in selected international markets.

Our ambition is to help critical-care teams act on timely clinical information and contribute to better outcomes for millions of people.

Market size, infrastructure and patient-reach figures are internal management estimates. Commercial-readiness and partnership statements are based on supplied investor materials. All statements are forward-looking and subject to investor verification.

Ready to invest in lives saved — and returns earned?

Join PlasmIT as a growth partner. Let's build the future of critical care together and make an impact that goes far beyond the balance sheet.